The company's proprietary Targeted Effector platform selectively delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules, ultimately improving outcomes for patients. MorphImmune's technology has the potential to easily drug previously undruggable physiological pathways in treating an array of illness mediated by the immune system at a lower cost.